-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Adaptimmune Therapeutics (NASDAQ:ADAP) Share Price Passes Above 50-Day Moving Average of $1.71
Adaptimmune Therapeutics (NASDAQ:ADAP) Share Price Passes Above 50-Day Moving Average of $1.71
Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) shares passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.71 and traded as high as $2.33. Adaptimmune Therapeutics shares last traded at $2.32, with a volume of 515,641 shares.
Adaptimmune Therapeutics Stock Performance
The business has a 50-day moving average price of $1.73 and a 200 day moving average price of $2.03.
Get Adaptimmune Therapeutics alerts:Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) last released its earnings results on Monday, May 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06). The business had revenue of $3.58 million during the quarter, compared to analysts' expectations of $4.00 million. Adaptimmune Therapeutics had a negative net margin of 1,500.43% and a negative return on equity of 86.57%. During the same quarter in the previous year, the company earned ($0.24) EPS. Sell-side analysts forecast that Adaptimmune Therapeutics plc will post -1.18 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Inspire Investing LLC acquired a new stake in shares of Adaptimmune Therapeutics during the fourth quarter worth approximately $58,000. Daiwa Securities Group Inc. increased its holdings in shares of Adaptimmune Therapeutics by 59.4% in the fourth quarter. Daiwa Securities Group Inc. now owns 24,515 shares of the biotechnology company's stock valued at $92,000 after purchasing an additional 9,133 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Adaptimmune Therapeutics by 13.6% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 69,140 shares of the biotechnology company's stock valued at $281,000 after purchasing an additional 8,292 shares in the last quarter. Syncona Portfolio Ltd acquired a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at approximately $5,165,000. Finally, DAFNA Capital Management LLC acquired a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at approximately $511,000.Adaptimmune Therapeutics Company Profile
(Get Rating)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Featured Stories
- Get a free copy of the StockNews.com research report on Adaptimmune Therapeutics (ADAP)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) shares passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.71 and traded as high as $2.33. Adaptimmune Therapeutics shares last traded at $2.32, with a volume of 515,641 shares.
在週四的交易中，Adaptimmune Treateutics公司(納斯達克代碼：ADAP-GET Rating)的股價超過了50日移動均線。該股的50日移動均線為1.71美元，交易價格高達2.33美元。Adaptimmune Treateutics的股票最後交易價格為2.32美元，成交量為515,641股。
Adaptimmune Therapeutics Stock Performance
Adaptimmune Treateutics股票表現
The business has a 50-day moving average price of $1.73 and a 200 day moving average price of $2.03.
該業務的50日移動均線價格為1.73美元，200日移動均線價格為2.03美元。
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) last released its earnings results on Monday, May 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06). The business had revenue of $3.58 million during the quarter, compared to analysts' expectations of $4.00 million. Adaptimmune Therapeutics had a negative net margin of 1,500.43% and a negative return on equity of 86.57%. During the same quarter in the previous year, the company earned ($0.24) EPS. Sell-side analysts forecast that Adaptimmune Therapeutics plc will post -1.18 earnings per share for the current fiscal year.
自適應免疫治療公司(納斯達克代碼：ADAP-GET評級)最近一次公佈收益結果是在5月9日星期一。這家生物技術公司公佈的季度每股收益(EPS)為0.32美元，低於分析師普遍預期的0.26美元和0.06美元。該業務本季度營收為358萬美元，高於分析師預期的400萬美元。Adaptimmune Treeutics的淨利潤率為負1,500.43%，淨資產回報率為負86.57%。去年同期，該公司每股收益為0.24美元。賣方分析師預測，Adaptimmune Treateutics plc本財年每股收益將達到1.18美元。
Institutional Inflows and Outflows
機構資金流入和流出
Adaptimmune Therapeutics Company Profile
Adaptimmune治療公司簡介
(Get Rating)
(獲取評級)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Adaptimmune Treateutics公司是一家臨牀階段的生物製藥公司，主要為美國和英國的實體腫瘤患者提供新型細胞療法。該公司的特定多肽增強親和力受體(SPEAR)T細胞平臺使其能夠識別癌症靶點。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Adaptimmune Therapeutics (ADAP)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 免費獲取StockNews.com關於Adaptimmune治療(ADAP)的研究報告
- MarketBeat：回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升，是時候收購了嗎？
- 蘋果為何可能在年底創下歷史新高
- Beyond Meat不是沒有希望，而且它很便宜
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《適應性免疫治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Adaptimmune Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧